Dr. Lori Goldstein on Neoadjuvant Treatment for HER2+ Breast Cancer

Lori J. Goldstein, MD
Published: Wednesday, Feb 04, 2015

Lori Goldstein, MD, the director of the Naomi and Phil Lippincott Breast Evaluation Center, Fox Chase Cancer Center, discusses a neoadjuvant trial of lapatinib and trastuzumab with or without endocrine therapy for 12 weeks vs. 24 weeks in patients with HER2 overexpressing breast cancer.

The study determined that a 24-week regimen was more effective than a 12 -week regimen.  While it is clear that a longer regimen is beneficial, it is unknown how this will impact overall survival, or if endocrine therapy given only before surgery has the same impact if given before and after surgery, says Goldstein.

Lori Goldstein, MD, the director of the Naomi and Phil Lippincott Breast Evaluation Center, Fox Chase Cancer Center, discusses a neoadjuvant trial of lapatinib and trastuzumab with or without endocrine therapy for 12 weeks vs. 24 weeks in patients with HER2 overexpressing breast cancer.

The study determined that a 24-week regimen was more effective than a 12 -week regimen.  While it is clear that a longer regimen is beneficial, it is unknown how this will impact overall survival, or if endocrine therapy given only before surgery has the same impact if given before and after surgery, says Goldstein.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x